Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Ethylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL234238 | 1.00 | TGFBR1 (0.31) | TGFBR1 | |
| Ethylene Glycol SCHEMBL990688 | 1.00 | TGFBR1 (0.31) | TGFBR1 | |
| Ethylene Glycol SCHEMBL990707 | 1.00 | TGFBR1 (0.31) | TGFBR1 | |
| Ethylene Glycol SCHEMBL233064 | 0.83 | TDP1 (0.35) | — | |
| Ethylene Glycol SCHEMBL233067 | 0.83 | TDP1 (0.35) | — | |
| SCHEMBL135673 | 0.80 | — | — | |
| Phosphoric Acid SCHEMBL2891155 | 0.77 | PPARD (0.31) | — | |
| Phosphoric Acid SCHEMBL2887125 | 0.77 | PPARD (0.31) | — | |
| Ethylene Glycol SCHEMBL27548536 | 0.77 | TSHR (0.39) | TGFBR1 | |
| SCHEMBL27510446 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | INHERIS BIOPHARMA INC (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-08-15 | — | — | US | disclosed |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-10143690-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180256563-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2018-09-13 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| EP-2628489-B1 | PEG oligomer-fentanyl conjugates | NEKTAR THERAPEUTICS (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20160375009-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2016-12-29 | — | — | US | disclosed |
| US-8569343-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2628489-A1 | PEG oligomer-fentanyl conjugates | Nektar Therapeutics (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8440687-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120289548-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2456469-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | Nektar Therapeutics (US) | 2012-05-30 | — | — | EP | disclosed |
| US-8173666-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2011011543-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-10143690-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-20180256563-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-20160375009-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-20120289548-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | TGFBR1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.